At a glance
ClinicalIndex Comparison RecordN/ACompleted· 65 enrolled
Drug / intervention
MDT-4107 Zotarolimus-Eluting Coronary Stentdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
RESOLUTE JAPAN SVS: The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary Stent in the Treatment of De Novo Lesions in Small Diameter Native Coronary Arteries
In Brief
A clinical study evaluating MDT-4107 Zotarolimus-Eluting Coronary Stent for Arterial Occlusive Diseases and 3 related conditions. Completed, enrolled 65 participants across 1 site.
Detailed Summary
The objective of the study is To verify the safety and efficacy of the MDT-4107 Drug-Eluting Coronary Stent in the treatment of de novo lesions in native coronary arteries with a reference vessel diameter (RVD) that allows the use of 2.25mm diameter stents.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArterial Occlusive Diseases, Myocardial Ischemia, Cardiovascular Diseases, Coronary Artery Disease
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedJun 2010
Primary CompletionOct 2011
Study CompletionJun 2016
TodayJul 2026
First PostedJun 25, 2010
Enrollment StartJun 1, 2010
Primary CompletionOct 1, 2011
Study CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.0 years ago
Interventions
MDT-4107 Zotarolimus-Eluting Coronary Stentdevice